Open Scanner

Specify a stock or a cryptocurrency in the search bar to get a summary

Internet Computer ICP
Bitcoin Cash BCH
Litecoin LTC
Field stub for analysis

Fulcrum Therapeutics Inc

FULC
Current price
4.99 USD +0.22 USD (+4.61%)
Last closed 4.8 USD
Sector Healthcare
Industry Biotechnology
Exchange NASDAQ
Capitalization 295 512 032 USD
Yield for 12 month -26.07 %
Week
Month
Year
FULC
21.11.2021 - 28.11.2021

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and FTX-6058, an investigational oral fetal hemoglobin inducer for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. Fulcrum Therapeutics, Inc. has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; and MyoKardia, Inc. to discover, develop, and commercialize novel targeted therapies for the treatment of genetic cardiomyopathies. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts. Address: 26 Landsdowne Street, Cambridge, MA, United States, 02139

Analytics

WallStreet Target Price

10.21 USD

P/E ratio

Dividend Yield

Current Year

+6 342 000 USD

Last Year

+19 163 000 USD

Current Quarter

+759 000 USD

Last Quarter

+880 000 USD

Current Year

+6 342 000 USD

Last Year

+19 163 000 USD

Current Quarter

+759 000 USD

Last Quarter

+880 000 USD

Key Figures FULC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
EBITDA -108 428 000 USD
Operating Margin TTM -3615.28 %
PE Ratio
Return On Assets TTM -26.27 %
PEG Ratio
Return On Equity TTM -41.4 %
Wall Street Target Price 10.21 USD
Revenue TTM 2 619 000 USD
Book Value 4.46 USD
Revenue Per Share TTM 0.044 USD
Dividend Share
Quarterly Revenue Growth YOY -35.8 %
Dividend Yield
Gross Profit TTM -70 440 000 USD
Earnings Share -1.66 USD
Diluted Eps TTM -1.66 USD
Most Recent Quarter III 2023
Quarterly Earnings Growth YOY
Profit Margin

Dividend Analytics FULC

Dividend growth over 5 years

Continuous growth

Payout Ratio 5 years average

Dividend History FULC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Forward Annual Dividend Rate
Ex Dividend Date
Forward Annual Dividend Yield
Last Split Factor
Payout Ratio
Last Split Date
Dividend Date

Stock Valuation FULC

1 year
3 years
5 years
10 years
21.11.2021 - 28.11.2021
Trailing PE
Forward PE
Enterprise Value Revenue 7.0377
Price Sales TTM 26.6208
Enterprise Value EBITDA -0.7166
Price Book MRQ 1.2789

Financials FULC

1 year
3 years
5 years
10 years
Results 2019 Dynamics

Technical indicators FULC

For 52 weeks

2.25 USD 15 USD
50 Day MA 3.97 USD
Shares Short Prior Month 3 909 815
200 Day MA 4.25 USD
Short Ratio 9.47
Shares Short 3 954 605
Short Percent 7.9 %